Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Thejew on Feb 16, 2019 12:03pm

249 Views

Post# 29375152

RE:RE:RE:RE:RE:RE:RE:RE:RE:DOCS are out ..

Your acting like almost every small bio doesn't do the exact same thing. You do realize this a penny bio right? It's all about these phase 2 results coming soon. If they are great, that's when a bigger play will either partner or buyout and dilution will be over.

They are now fully funded for the these trials, so dilution is basically done. Great time to enter.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?